
Cobimetinib
CAS No. 934660-93-2
Cobimetinib ( GDC-0973 | XL-518 | GDC 0973 | XL 518 | GDC0973 | XL518 )
产品货号. M16682 CAS No. 934660-93-2
Cobimetinib (GDC-0973, XL-518) 是一种有效的选择性 MEK 抑制剂,对 MEK1 的 IC50 为 4.2 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥381 | 有现货 |
![]() ![]() |
5MG | ¥624 | 有现货 |
![]() ![]() |
10MG | ¥786 | 有现货 |
![]() ![]() |
25MG | ¥1482 | 有现货 |
![]() ![]() |
50MG | ¥2357 | 有现货 |
![]() ![]() |
100MG | ¥3864 | 有现货 |
![]() ![]() |
500MG | ¥7995 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Cobimetinib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Cobimetinib (GDC-0973, XL-518) 是一种有效的选择性 MEK 抑制剂,对 MEK1 的 IC50 为 4.2 nM。
-
产品描述Cobimetinib (GDC-0973, XL-518) is a potent, selective MEK inhibitor with IC50 of 4.2 nM for MEK1; shows excellent selectivity against mTOR, DNA-dependent protein kinase (DNA-PK), and a panel of more than 228 kinases; shows strong cellular potency in a broad panel of tumor types, particularly in BRAF or KRAS mutant cancer cell lines, triggers robust apoptosis and tumor growth inhibition in vivo combined with PI3K inhibitor GDC-0941.Skin Cancer Approved(In Vitro):The EC50 values of Cobimetinib (GDC-0973) for 888MEL and A2058 cells are 0.2 μM, 10 μM, respectivelly. Melanoma cells are treated with EC50 concentration of MEK and PI3K inhibitors for 24 hours (888MEL: 0.05 μM GDC-0973, 2.5 μM GDC-0941; A2058: 2.5 μM GDC-0973, 2.5 μM GDC-0941). Mitochondrial OXPHOS limits cell death induced by cobimetinib (100 nM) in melanoma with constitutive MAPK activation in A375 cells.(In Vivo):In the NCI-H2122 KRASG12C mutant non-small cell lung carcinoma (NSCLC) xenograft model, treatment with up to 5 mg/kg Cobimetinib (GDC-0973) lead to moderate TGI and at 10 mg/kg approaches tumor stasis. GDC-0973 and GDC-0941 are administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as single agents or in combination. The population rate constants associated with tumor growth inhibition for GDC-0973 and GDC-0941 are 0.00102 and 0000651 μM-1 h-1, respectively. Following single doses of GDC-0973 (1, 3, or 10 mg/kg, p.o.) estimated in vivo IC50 values of %pERK decrease based on tumor concentrations in xenograft mice are 0.78 (WM-266-4) and 0.52 μM (A375).
-
体外实验——
-
体内实验——
-
同义词GDC-0973 | XL-518 | GDC 0973 | XL 518 | GDC0973 | XL518
-
通路MAPK/ERK Signaling
-
靶点MEK
-
受体MEK1
-
研究领域Cancer
-
适应症Skin Cancer
化学信息
-
CAS Number934660-93-2
-
分子量531.31
-
分子式C21H21F3IN3O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESC1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
-
化学全称Methanone, [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-[(2S)-2-piperidinyl]-1-azetidinyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Hoeflich KP, et al. Cancer Res. 2012 Jan 1;72(1):210-9.
2. Wong H, et al. Clin Cancer Res. 2012 Jun 1;18(11):3090-9.
3. Rice KD, et al. ACS Med Chem Lett. 2012 Apr 9;3(5):416-21.
4. Ribas A, et al. Lancet Oncol. 2014 Aug;15(9):954-65.
产品手册




关联产品
-
MKK7-COV-9
MKK7-COV-9(MKK7 Covalen 抑制剂 9)是一种有效的、选择性的共价 MKK7 抑制剂。
-
MEKK2 inhibitor 1s
MEKK2抑制剂1s (MEKK2-IN-1s)是一种有效的MEKK2 (MAP3K2)抑制剂,IC50为16 nM,以相似的效力抑制MEKK2和MEKK3。
-
MEK-IN-4
MEK-IN-4 是一种 MEK 抑制剂。MEK-IN-4 可用于炎症性疾病和癌症的研究。